Erythropoietin in thyroid cancer

Journal of Endocrinological Investigation

Volumn 29, Issue 4, 2006, Pages 320-329

  Yates, C M ^a,b   Patel, A ^a   Oakley, K ^a   Helms, A ^a   Tuttle, R M ^c   Francis, G L ^a,d  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^b WALTER REED ARMY MEDICAL CENTER   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer; Erythropoietin; Gene; Hypoxia; Thyroid

Indexed keywords

BETA CASEIN; CATHEPSIN D; COBALT; CYCLOOXYGENASE 2; ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; MESSENGER RNA; MITOCHONDRIAL PROTEIN; PROTEIN WIG1; SOMATOMEDIN C; THYROTROPIN; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANAPLASTIC CARCINOMA; ARTICLE; CANCER CELL CULTURE; CARCINOGENESIS; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; SIGNAL TRANSDUCTION; THYROID CANCER; THYROID FOLLICULAR CARCINOMA; THYROID PAPILLARY CARCINOMA;

EID: 33745223865     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03344103     Document Type: Article

References (54)

1. Yu X, Lin CS, Costantini F, Noguchi CT. The human erythropoietin receptor gene rescues erythropoiesis and developmental defects in the erythropoietin receptor null mouse. Blood 2001, 98: 475-7.
2. Yu X, Shacka JJ, Eells JB, et al. Erythropoietin receptor signalling is required for normal brain development. Development 2002, 129: 505-16.
3. Yasuda Y, Matsuo T, Nagao M. Blockade of erythropoietin signal at the early postimplantation period inhibits the development of decidua and embryo in mice. Congenit Anom (Kyoto) 2004, 44: 9-17.
4. Conrad KP, Benyo DF, Westerhausen-Larsen A, Miles TM. Expression of erythropoietin by the human placenta. FASEB J 1996, 10: 760-8.
5. Dame C, Fahnenstich H, Freitag P, et al. Erythropoietin mRNA expression in human fetal and neonatal tissue. Blood 1998, 92: 3218-25.
6. Juul SE, Anderson DK, Li Y, Christensen RD. Erythropoietin and erythropoietin receptor in the developing human central nervous system. Pediatr Res 1998, 43: 40-9.
7. Acs G, Zhang PJ, McGrath CM, et al. Hypoxia-inducible erythropoietin signaling in squamous clysplasia and squamous cell carcinoma of the uterine cervix and its potential role in cervical carcinogenesis and tumor progression. Am J Pathol 2003, 162: 1789-806.
8. Acs G, Xu X, Chu C, Acs P, Verma A. Prognostic significance of erythropoietin expression in human endometrial carcinoma. Cancer 2004, 100: 2376-86.
9. Yasuda Y, Masuda S, Chikuma M, Inoue K, Nagao M, Sasaki R. Estrogen-dependent production of erythropoietin in uterus and its implication in uterine angiogenesis. J Biol Chem 1998, 273: 25381-7.
10. Yasuda Y, Fujita Y, Musha T, et al. Expression of erythropoietin in human female reproductive organs. Ital J Anat Embryol 2001, 106: 215-22.
11. Yasuda Y, Musha T, Tanaka H, et al. Inhibition of erythropoietin signalling destroys xenografts of ovarian and uterine cancers in nude mice. Br J Cancer 2001, 84: 836-43.
12. Yasuda Y, Fujita Y, Masuda S, et al. Erythropoietin is involved in growth and angiogenesis in malignant tumours of female reproductive organs. Carcinogenesis 2002, 23: 1797-805.
13. Sakanaka M, Wen TC, Matsuda S, et al. In vivo evidence that erythropoietin protects neurons from ischemic damage. Proc Natl Acad Sci USA 1998, 95: 4635-40.
14. Celik M, Gokmen N, Erbayraktar S, et al. Erythropoietin prevents motor neuron apoptosis and neurologic disability in experimental spinal cord ischemic injury. Proc Natl Acad Sci U S A 2002, 99: 2258-63.
15. Kawakami M, Sekiguchi M, Sato K, Kozaki S, Takahashi M. Erythropoietin receptor-mediated inhibition of exocytotic glutamate release confers neuroprotection during chemical ischemia. J Biol Chem 2001, 276: 39469-75.
16. Juul S. Erythropoietin in the central nervous system, and its use to prevent hypoxic-ischemic brain damage. Acta Paediatr 2002, 91 (Suppl): 36-42.
17. Morishita E, Masuda S, Nagao M, Yasuda Y, Sasaki R. Erythropoietin receptor is expressed in rat hippocampal and cerebral cortical neurons, and erythropoietin prevents in vitro glutamate-induced neuronal death. Neuroscience 1997, 76: 105-16.
18. Marti HH, Wenger RH, Rivas LA, et al. Erythropoietin gene expression in human, monkey and murine brain. Eur J Neurosci 1996, 8: 666-76.
19. Acs G, Acs P, Beckwith SM, et al. Erythropoietin and erythropoietin receptor expression in human cancer. Cancer Res 2001, 61: 3561-5.
20. Acs G, Zhang PJ, Rebbeck TR, Acs P, Verma A. Immunohistochemical expression of erythropoietin and erythropoietin receptor in breast carcinoma. Cancer 2002, 95: 969-81.
21. Longmore GD, Lodish HF. An activating mutation in the murine erythropoietin receptor induces erythroleukemia in mice: a cytokine receptor superfamily oncogene. Cell 1991, 67: 1089-102.
22. Batra S, Perelman N, Luck LR, Shimada H, Malik P. Pediatric tumor cells express erythropoietin and a functional erythropoietin receptor that promotes angiogenesis and tumor cell survival. Lab Invest 2003, 83: 1477-87.
23. Yasuda Y, Fujita Y, Matsuo T, et al. Erythropoietin regulates tumour growth of human malignancies. Carcinogenesis 2003, 24: 1021-9.
24. Acs G, Chen M, Xu X, Acs P, Verma A, Koch CJ. Autocrine erythropoietin signaling inhibits hypoxia-incluced apoptosis in human breast carcinoma cells. Cancer Lett 2004, 214: 243-51.
25. Silva M, Benito A, Sanz C, et al. Erythropoietin can induce the expression of bcl-x(L) through Stat5 in erythropoietin-dependent progenitor cell lines. J Biol Chem 1999, 274: 22165-9.
26. Arcasoy MO, Amin K, Karayal AF, et al. Functional significance of erythropoietin receptor expression in breast cancer. Lab Invest 2002, 82: 911-8.
27. Eccles TG, Patel A, Verma A, et al. Erythropoietin and the erythropoietin receptor are expressed by papillary thyroid carcinoma from children and adolescents. Expression of erythropoietin receptor might be a favorable prognostic indicator. Ann Clin Lab Sci 2003, 33: 411-22.
28. Smith RJ, Contrera JF. Cobalt-induced alterations in plasma proteins, proteases and kinin system of the rat. Biochem Pharmacol 1974, 23: 1095-103.
29. Schuster SJ, Badiavas EV, Costa-Giomi P, Weinmann R, Erslev AJ, Caro J. Stimulation of erythropoietin gene transcription during hypoxia and cobalt exposure. Blood 1989, 73: 13-6.
30. Miura O, Cleveland JL, Ihle JN. Inactivation of erythropoietin receptor function by point mutations in a region having homology with other cytokine receptors. Mol Cell Biol 1993, 13: 1788-95.
31. Takahashi T, Chiba S, Hirano N, Yazaki Y, Hirai H. Characterization of three erythropoietin (Epo)-binding proteins in various human Epo-responsive cell lines and in cells transfected with human Epo-receptor cDNA. Blood 1995, 85: 106-14.
32. Longmore GD, Watowich SS, Hilton DJ, Lodish HF. The erythropoietin receptor: its role in hematopoiesis and myeloproliferative diseases. J Cell Biol 1993, 123: 1305-8.
33. Miura Y, Miura O, Ihle JN, Aoki N. Activation of the mitogen-activated protein kinase pathway by the erythropoietin receptor. J Biol Chem 1994, 269: 29962-9.
34. Salceda S, Caro J. Hypoxia-inclucible factor 1alpha (HIF-1alpha) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes. J Biol Chem 1997, 272: 22642-7.
35. Srinivas V, Zhu X, Salceda S, Nakamura R, Caro J. Hypoxiainducible factor 1alpha (HIF-1alpha) is a non-heme iron protein. Implications for oxygen sensing. J Biol Chem 1998, 273: 18019-22.
36. Yamashita H, Osaki M, Ardyanto TD, Yoshida H, Ito H. Cyclooxygenase-2 in human malignant fibrous histiocytoma: correlations with intratumoral microvessel density, expression of vascular endothelial growth factor and thymidine phosphorylase. Int J Mol Med 2004, 14: 565-70.
37. Ito Y, Yoshida H, Nakano K, et al. Cyclooxygenase-2 expression in thyroid neoplasms. Histopathology 2003, 42: 492-7.
38. Kase S, Osaki M, Honjo S, et al. Expression of cyclooxygenase-1 and cyclooxygenase-2 in human esophageal mucosa, dysplasia and carcinoma. Pathobiology 2004, 71: 84-92.
39. Bamba H, Ota S, Kato A, Adachi A, Itoyama S, Matsuzaki F. High expression of cyclooxygenase-2 in macrophages of human colonic adenoma. Int J Cancer 1999, 83: 470-5.
40. Yamamoto H, Itoh F, Fukushima H, Hinoda Y, Imai K. Overexpression of cyclooxygenase-2 protein is less frequent in gastric cancers with microsatellite instability. Int J Cancer 1999, 84: 400-3.
41. Kajita S, Ruebel KH, Casey MB, Nakamura N, Lloyd RV. Role of COX-2, thromboxane A(2) synthase, and prostaglandin I(2) synthase in papillary thyroid carcinoma growth. Mod Pathol 2005, 18: 221-7.
42. Siironen P, Ristimaki A, Nordling S, Louhimo J, Haapiainen R, Haglund C. Expression of COX-2 is increased with age in papillary thyroid cancer. Histopathology 2004, 44: 490-7.
43. Fuste B, Serradell M, Escolar G, et al. Erythropoietin triggers a signaling pathway in endothelial cells and increases the thrombogenicity of their extracellular matrices in vitro Thromb Haemost 2002, 88: 678-85.
44. Bode-Boger SM, Boger RH, Kuhn M, Radermacher J, Frolich JC. Enclothelin release and shift in prostaglandin balance are involved in the modulation of vascular tone by recombinant erythropoietin. J Cardiovasc Pharmacol 1992, 20 (Suppl): 525-8.
45. Oda A, Sawada K, Druker BJ, et al. Erythropoietin induces tyrosine phosphorylation of Jak2, STAT5A, and STAT5B in primary cultured human erythroid precursors. Blood 1998, 92: 443-51.
46. Witthuhn BA, Quelle FW, Silvennoinen O, et al. JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin. Cell 1993, 74: 227-36.
47. Wakao H, Gouilleux F, Groner B. Mammary gland factor (MGF) is a novel member of the cytokine regulated transcription factor gene family and confers the prolactin response. EMBO J 1994, 13: 2182-91.
48. Kozlowski L, Wojtukiewicz MZ. The role of proteolytic enzymes in skin neoplasm progression and development of metastasis. Postepy Hig Med Dosw 1999, 53: 841-54.
49. Ying H, Suzuki H, Furumoto H, et al. Alterations in genomic profiles during tumor progression in a mouse model of follicular thyroid carcinoma. Carcinogenesis 2003, 24: 1467-79.
50. Ruhoy SM, Clarke MR. Cathepsin B and cathepsin D expression in follicular adenomas and carcinomas of the thyroid gland. Endocr Pathol 1997, 8: 49-57.
51. Tomasevic G, Shamloo M, Israeli D, Wieloch T. Activation of p53 and its target genes p21 (WAF1/Cip1) and PAG608/Wig-1 in ischemic preconditioning. Brain Res Mol Brain Res 1999, 70: 304-13.
52. Polyak K, Xia Y, Zweier JL, Kinzler KW, Vogelstein B. A model for p53-induced apoptosis. Nature 1997, 389: 300-5.
53. Israeli D, Tessler E, Haupt Y, et al. A novel p53-inducible gene, PAG608, encodes a nuclear zinc finger protein whose overexpression promotes apoptosis. EMBO J 1997, 16: 4384-92.
54. Hellborg F, Qian W, Mendez-Vidal C, et al. Human wig-1, a p53 target gene that encodes a growth inhibitory zinc finger protein. Oncogene 2001, 20: 5466-74.